Insights into Behcet's disease

被引:3
作者
Shahneh, Fatemeh Zare [2 ]
Babalo, Zohreh [1 ]
Baradaran, Behzad [2 ]
Sepehr, Koushan Sineh
机构
[1] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Tabriz, Iran
[2] Tabriz Univ Med Sci, IRC, Tabriz, Iran
来源
POSTEPY DERMATOLOGII I ALERGOLOGII | 2012年 / 29卷 / 06期
关键词
Behcet's disease; autoinflammatory; immunogenetics; gene polymorphisms; cytokines; REGULATORY T-CELLS; HLA CLASS-I; GENE POLYMORPHISMS; IRANIAN PATIENTS; ASSOCIATION; HLA-B-ASTERISK-51; MANIFESTATIONS; SUSCEPTIBILITY; INFLIXIMAB; ALLELES;
D O I
10.5114/pdia.2012.32395
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Behcet's disease is a chronic relapsing multi-organ inflammatory disorder characterized as a triad of oral and genital ulcers, uveitis. Characteristic manifestations of Behcet's disease are joints, skin, central nervous system and gastrointestinal tract involvement. Behcet's disease has a complicated genetic etiology. However, epidemiological studies recommend that genetic factors have a significant role in its pathogenesis, the same as other autoinflammatory disorders. Antigenic stimuli, antigen-presenting cells, T cells, monocyte, neutrophil and endothelial cells are most important parts of the pathology of the disease. Inflammatory response was triggered by an infectious agent in a genetically susceptible host. Understanding the pathogenesis based on the molecular mechanism of the disease highlights the new therapeutic modalities. Enhanced inflammatory activity and over-expression of proinflammatory cytokines are the striking features of Behcet's disease, and they are accordant with the result in other auto inflammatory disorders. Moreover, there is evidence of antigen-driven immune response in Behcet's disease, but it probably advances in further innate immune reactivity. New therapeutic modalities target specific and nonspecific suppression of the immune system. The diagnosis is a clinical one, and although there is no single laboratory test enough for the diagnosis of Behcet's disease. In this paper, a new aspect of the studies on genetic susceptibility, immunopathogenesis of Behcet's disease and novel treatment modalities will be discussed.
引用
收藏
页码:461 / 466
页数:6
相关论文
共 80 条
[1]  
[Anonymous], 2012, PATHOLOG RES INT
[2]   Anti-TNF Agents for Behcet's Disease: Analysis of Published Data on 369 Patients [J].
Arida, Aikaterini ;
Fragiadaki, Kalliopi ;
Giavri, Eirini ;
Sfikakis, Petros P. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (01) :61-70
[3]   The relationship between serum prolactin levels and disease activity in patients with Behcet's disease [J].
Atasoy, Mustafa ;
Karatay, Saliha ;
Yildirim, Kadir ;
Kadi, Melek ;
Erdem, Teoman ;
Senel, Kazim .
CELL BIOCHEMISTRY AND FUNCTION, 2006, 24 (04) :353-356
[4]   SEROLOGICAL AND MOLECULAR HLA TYPING IN ITALIAN BEHCET PATIENTS - SIGNIFICANT ASSOCIATION TO B51-DR5-DQW3 HAPLOTYPE [J].
BALBONI, A ;
PIVETTIPEZZI, P ;
ORLANDO, P ;
RUBINI, M ;
SELVATICI, R ;
ACCORINTI, M ;
BARICORDI, OR ;
GANDINI, E .
TISSUE ANTIGENS, 1992, 39 (03) :141-143
[5]   Detection of parvovirus B19 DNA in the lesional skin of patients with Behcet's disease [J].
Baskan, E. B. ;
Yilmaz, E. ;
Saricaoglu, H. ;
Alkan, G. ;
Ercan, I. ;
Mistik, R. ;
Adim, S. B. ;
Goral, G. ;
Dilek, K. ;
Tunali, S. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2007, 32 (02) :186-190
[6]   The Use of Biologic Agents in the Treatment of Ocular Manifestations of Behcet's Disease [J].
Benitah, Nicole R. ;
Sobrin, Lucia ;
Papaliodis, George N. .
SEMINARS IN OPHTHALMOLOGY, 2011, 26 (4-5) :295-303
[7]  
Bonyadi M, 2009, RHEUMATOL INT, V23, P1
[8]   Infliximab for patients with neuro-Behcet's disease: case series and literature review [J].
Borhani Haghighi, Afshin ;
Safari, Anahid ;
Nazarinia, Mohammad Ali ;
Habibagahi, Zahra ;
Shenavandeh, Saeedeh .
CLINICAL RHEUMATOLOGY, 2011, 30 (07) :1007-1012
[9]   Tocilizumab may be a potential addition to our weapons against neuro-Behcet's disease [J].
Borhani-Haghighi, Afshin ;
Safari, Anahid .
MEDICAL HYPOTHESES, 2008, 71 (01) :156-157
[10]  
Briani C, 2006, CLIN EXP RHEUMATOL, V24, pS104